Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE
29 févr. 2016 09h00 HE
|
Kannalife, Inc.
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...